Literature DB >> 15986340

The many worlds of reducing interleukin-1.

Charles A Dinarello.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15986340     DOI： 10.1002/art.21107

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  25 in total

1.  An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX).

Authors:  Norma Jung; Matthias Hellmann; Reimund Hoheisel; Clara Lehmann; Ingo Haase; Andreas Perniok; Michael Hallek; Andrea Rubbert
Journal:  Clin Rheumatol       Date:  2010-06-09       Impact factor: 2.980

Review 2.  Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Authors:  Pauline L Martin; Peter J Bugelski
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  Ex vivo interleukin 1 receptor antagonist production on lipopolysaccharide stimulation is associated with rheumatoid arthritis and with joint damage.

Authors:  J K de Vries-Bouwstra; Y P M Goekoop-Ruiterman; J Wesoly; H J Hulsmans; A J M de Craen; F C Breedveld; B A C Dijkmans; C F Allaart; T W J Huizinga
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

Review 4.  The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders.

Authors:  H E Barksby; S R Lea; P M Preshaw; J J Taylor
Journal:  Clin Exp Immunol       Date:  2007-06-21       Impact factor: 4.330

5.  XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases.

Authors:  Alexander M Owyang; Hassan Issafras; John Corbin; Kiran Ahluwalia; Paul Larsen; Elizabeth Pongo; Masahisa Handa; Arnold H Horwitz; Marina K Roell; Mary Haak-Frendscho; Linda Masat
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

Review 6.  Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes.

Authors:  Thomas Mandrup-Poulsen
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 7.  Affective disturbance in rheumatoid arthritis: psychological and disease-related pathways.

Authors:  John A Sturgeon; Patrick H Finan; Alex J Zautra
Journal:  Nat Rev Rheumatol       Date:  2016-07-14       Impact factor: 20.543

8.  Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties.

Authors:  Hassan Issafras; John A Corbin; Ira D Goldfine; Marina K Roell
Journal:  J Pharmacol Exp Ther       Date:  2013-11-05       Impact factor: 4.030

9.  A broad analysis of IL1 polymorphism and rheumatoid arthritis.

Authors:  Alyssa K Johnsen; Robert M Plenge; Vincent Butty; Christopher Campbell; Rebeca Dieguez-Gonzalez; Juan J Gomez-Reino; Nancy Shadick; Michael Weinblatt; Antonio Gonzalez; Peter K Gregersen; Christophe Benoist; Diane Mathis
Journal:  Arthritis Rheum       Date:  2008-07

Review 10.  Microarray-based identification of novel biomarkers in IL-1-mediated diseases.

Authors:  Florence Allantaz; Damien Chaussabel; Jacques Banchereau; Virginia Pascual
Journal:  Curr Opin Immunol       Date:  2007-11-26       Impact factor: 7.486
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.